Blueprint Medicines
Blueprint Medicines, a Sanofi company, develops precision kinase-targeted therapies for systemic mastocytosis, PDGFRA-mutant GIST, and other rare allergic/inflammatory and oncology diseases. Lead product AYVAKIT (avapritinib) is approved in the U.S. and Europe.
- Company typePrivate
- Founded2015
- HeadquartersCambridge, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Blueprint Medicines does
Blueprint Medicines, a Sanofi company since June 2025, is a biopharmaceutical firm headquartered in Cambridge, Massachusetts that develops precision kinase-targeted therapies for genomically defined cancers and rare allergic/inflammatory diseases. The company's core technology is a proprietary kinase-targeted drug discovery platform designed to produce highly selective small molecules that address the underlying biology of diseases driven by specific kinase mutations, particularly KIT and PDGFRA. Its approved product AYVAKIT (avapritinib) is a KIT and PDGFRA inhibitor approved in the U.S. and Europe for adults with indolent systemic mastocytosis, advanced systemic mastocytosis, and unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring PDGFRA exon 18 mutations including D842V. The pipeline includes elenestinib (BLU-263), a KIT inhibitor in development for systemic mastocytosis, and BLU-808, a planned candidate for chronic urticaria and other mast cell-mediated diseases.
The business model is commercial-stage specialty biopharma: revenue is generated primarily through global product sales of AYVAKIT, distributed via specialty pharmacy channels with a dedicated patient support program (YourBlueprint) providing access, co-pay, and adherence support. The go-to-market motion relies on specialty field sales teams and medical science liaisons targeting hospitals, academic medical centers, and specialty pharmacies, supplemented by medical conference presence (AAAAI, ASH, EAACI), digital properties, and direct medical-information channels. Post-acquisition, Blueprint's commercial reach is amplified by Sanofi's global specialty/immunology infrastructure, while its products are made available outside the U.S. and China through marketing authorizations and a Named Patient Program.
Customer segments are organized by rare disease indication rather than enterprise buyer: indolent systemic mastocytosis patients (primary), advanced systemic mastocytosis patients (aggressive SM, SM-AHN, mast cell leukemia), and GIST patients with PDGFRA exon 18 mutations. Payer mix is fragmented across commercial insurers and government programs typical for high-cost rare disease therapies, with pricing disclosed under state transparency requirements. The company was acquired by Sanofi for approximately $9.5 billion ($129 per share plus milestone payments), validating the franchise value of its kinase precision medicine platform.
Blueprint Medicines firmographics
Firmographics- Name
- Blueprint Medicines
- Legal name
- Blueprint Medicines Corporation
- Website
- https://blueprintmedicines.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Acquired
- Headcount range
- 501–1,000 employees
- Short description
- Blueprint Medicines, a Sanofi company, develops precision kinase-targeted therapies for systemic mastocytosis, PDGFRA-mutant GIST, and other rare allergic/inflammatory and oncology diseases. Lead product AYVAKIT (avapritinib) is approved in the U.S. and Europe.
- Ownership category
- akta.pro rank
Blueprint Medicines industry classification
Industry- Product category
- Precision Oncology Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Mast Cell Disorders Specialty Care (HLAKAAAH)
- akta.pro secondary industries
- Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)
Keywords
Where Blueprint Medicines is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Blueprint Medicines business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Product Sales (AYVAKIT): Revenue generated from global sales of AYVAKIT (avapritinib) for approved indications in indolent systemic mastocytosis, advanced systemic mastocytosis, and GIST. As a Sanofi company post-acquisition, product revenues contribute to Sanofi's portfolio.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | AYVAKIT (avapritinib) - various dosage forms |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Blueprint Medicines product offering
Product offeringCore offering
Blueprint Medicines develops and commercializes precision kinase-targeted therapies, most notably AYVAKIT (avapritinib), a KIT and PDGFRA inhibitor approved in the U.S. and Europe for adults with indolent systemic mastocytosis, advanced systemic mastocytosis, and unresectable or metastatic GIST harboring PDGFRA exon 18 mutations. The pipeline includes elenestinib (BLU-263) in development for systemic mastocytosis and BLU-808 for chronic urticaria and other mast cell-mediated diseases.
Product overview
Blueprint Medicines is a biopharmaceutical company that develops precision-targeted therapies for systemic mastocytosis and other allergic/inflammatory diseases and cancer. The company's approved product AYVAKIT (avapritinib) addresses KIT-mediated diseases including indolent and advanced systemic mastocytosis and GIST. The pipeline includes elenestinib (BLU-263) for systemic mastocytosis indications and BLU-808 for chronic urticaria and mast cell-mediated diseases. Following Sanofi's acquisition in 2025, the company operates as part of the Sanofi portfolio while maintaining its focused drug development approach.
Differentiator
Problem solved
Functional benefit
Brands
- AYVAKIT: Avapritinib - approved drug for indolent systemic mastocytosis, advanced systemic mastocytosis, and unresectable or metastatic gastrointestinal stromal tumor (GIST) with PDGFRA exon 18 mutation
- YourBlueprint
Products and services
- AYVAKIT (avapritinib) AYVAKIT is an approved precision therapy targeting KIT and PDGFRA mutations, indicated for adults with indolent systemic mastocytosis, advanced systemic mastocytosis, and unresectable or metastatic GIST harboring PDGFRA exon 18 mutations including the D842V mutation.
- Elenestinib (BLU-263) Elenestinib is a development-stage KIT inhibitor being studied for treatment of indolent systemic mastocytosis and advanced systemic mastocytosis.
- BLU-808 BLU-808 is a planned development program targeting chronic spontaneous and inducible urticaria and additional common mast cell-mediated diseases.
Quantifiable outcome
- 46.5-month median follow-up with sustained symptom control and quality of life improvements in ISM patients
- +4 more outcomes
Companies that use Blueprint Medicines
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Blueprint Medicines technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Blueprint Medicines partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- SanofiflagshipSanofi acquired Blueprint Medicines Corporation for approximately $9.5 billion (up to $9.5B with milestone payments), expanding Sanofi's rare immunological disease portfolio and pipeline. The acquisition included marketed drugs AYVAKIT (avapritinib) and early-stage candidates. Blueprint now operates as a Sanofi company. Deal closed Q3 2025.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Blueprint Medicines competitors and assessment
Company assessmentDirect peers
- Deciphera Pharmaceuticals: Develops Qinlock (ripretinib) for GIST, making it a direct competitor to AYVAKIT in kinase-driven GIST treatment with overlapping prescriber audiences.
- Exelixis: Markets Cabometyx (cabozantinib) for advanced GIST after prior therapy, overlapping with Blueprint's PDGFRA-mutant GIST positioning and kinase-inhibitor oncology expertise.
- Novartis: Markets Rydapt (midostaurin), the other approved multikinase inhibitor for advanced systemic mastocytosis, making it Blueprint's most direct competitor in the KIT-driven SM market.
Emerging players
- Allakos: Focused on mast cell and eosinophil-driven diseases, with adjacent programs in chronic urticaria and other mast cell-mediated conditions targeted by Blueprint's BLU-808.
- Cogent Biosciences: Developing bezuclastinib for systemic mastocytosis and GIST, positioning it as the most advanced late-stage challenger to Blueprint's AYVAKIT franchise in both ISM and advanced SM.
Broad incumbents
- Sanofi: Acquired Blueprint Medicines in 2025 and operates it as a wholly-owned subsidiary; Sanofi is also a broad incumbent in immunology, rare disease, and oncology with overlapping kinase and inflammatory portfolios.
- AbbVie: Large immunology and oncology incumbent with deep rare disease commercial infrastructure; pursues precision oncology and allergic/inflammatory disease programs adjacent to Blueprint's focus areas.
- AstraZeneca: Oncology and rare disease major with kinase inhibitor expertise (e.g., Tagrisso) and growing immunology footprint, making it both a potential competitor and strategic acquirer for precision rare disease assets.
- Bristol-Myers Squibb: Major biopharmaceutical company with deep oncology and immunology pipelines, including kinase inhibitors and rare hematology assets adjacent to Blueprint's SM and GIST franchises.
- Pfizer: Diversified biopharmaceutical incumbent with precision oncology, rare disease, and immunology capabilities that overlap with Blueprint's kinase-targeted rare disease focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Blueprint Medicines social profiles
Digital presenceBlueprint Medicines compliance and trust
Trust signalCompliance4 records
Blueprint Medicines financial estimates
Financial estimateRevenue estimate
Valuation estimate
Blueprint Medicines leadership team
Management profileNumber of profiles
Profiles13 records
Blueprint Medicines funding detail
Funding detailFunding overview
Funding rounds10 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Blueprint Medicines M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Blueprint Medicines
What does Blueprint Medicines do?
Blueprint Medicines develops and commercializes precision kinase-targeted therapies, most notably AYVAKIT (avapritinib), a KIT and PDGFRA inhibitor approved in the U.S. and Europe for adults with indolent systemic mastocytosis, advanced systemic mastocytosis, and unresectable or metastatic GIST harboring PDGFRA exon 18 mutations. The pipeline includes elenestinib (BLU-263) in development for systemic mastocytosis and BLU-808 for chronic urticaria and other mast cell-mediated diseases.
Is Blueprint Medicines a public or private company?
Blueprint Medicines is a private company. It is classified as corporate owned and is currently acquired.
When was Blueprint Medicines founded?
Blueprint Medicines was founded in 2015. It employs 501 to 1,000 people.
Where is Blueprint Medicines based?
Blueprint Medicines is headquartered in Cambridge, United States, in the North America region.
How does Blueprint Medicines make money?
One revenue line is on record: product Sales (AYVAKIT).
Who are Blueprint Medicines's main competitors?
Direct peers on record are Deciphera Pharmaceuticals, Exelixis and Novartis. Emerging players are Allakos and Cogent Biosciences. Broad incumbents are Sanofi, AbbVie, AstraZeneca, Bristol-Myers Squibb and Pfizer.
Does Blueprint Medicines have an API?
No public API is recorded for Blueprint Medicines.
What industry is Blueprint Medicines in?
Blueprint Medicines's product category is Precision Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAKAAAH, Mast Cell Disorders Specialty Care, with a secondary code of HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 3254 and its SIC code is 2834.